Medical Genetics Summaries (National Institutes of Health), MGS
General information
Medical Genetics Summaries, MGS
National Institutes of Health
9000 Rockville Pike
Bethesda
Maryland
United States
https://www.ncbi.nlm.nih.gov/books/NBK61999/
Organization ID: 506575
National Institutes of Health
9000 Rockville Pike
Bethesda
Maryland
United States
https://www.ncbi.nlm.nih.gov/books/NBK61999/
Organization ID: 506575
Assertion criteria
Level: Assertion criteria provided
- Deutetrabenazine Therapy and CYP2D6 Genotype
- Medical Genetics Summaries: Flurbiprofen Therapy and CYP2C9 Genotype
- Medical Genetics Summaries: Gentamicin therapy and MT-RNR1 genotype
- Medical Genetics Summaries: Irinotecan therapy and UGT1A1 genotype
- Medical Genetics Summaries: Lesinurad Therapy and CYP2C9 Genotype
- Medical Genetics Summaries: Piroxicam Therapy and CYP2C9 Genotype
- Tamoxifen Therapy and CYP2D6 Genotype
Summary of submissions to ClinVar
Total submissions: 37
Gene
| Gene | Submissions | Last Updated |
|---|---|---|
| CYP2C9 | 18 | Mar 19, 2019 |
| CYP2D6 | 11 | Mar 6, 2020 |
| MT-ND1 | 1 | Sep 12, 2018 |
| MT-RNR1 | 3 | Sep 12, 2018 |
| MT-TS1 | 1 | Sep 12, 2018 |
| UGT1A | 5 | Jun 29, 2018 |
| UGT1A1 | 5 | Jun 29, 2018 |
| UGT1A10 | 5 | Jun 29, 2018 |
| UGT1A3 | 5 | Jun 29, 2018 |
| UGT1A4 | 5 | Jun 29, 2018 |
| UGT1A5 | 5 | Jun 29, 2018 |
| UGT1A6 | 5 | Jun 29, 2018 |
| UGT1A7 | 5 | Jun 29, 2018 |
| UGT1A8 | 5 | Jun 29, 2018 |
| UGT1A9 | 5 | Jun 29, 2018 |
Condition
| Name | Submissions | Last Updated |
|---|---|---|
| Deutetrabenazine response | 5 | Nov 7, 2019 |
| Flurbiprofen response | 6 | Mar 19, 2019 |
| Gentamicin response | 3 | Sep 12, 2018 |
| Irinotecan response | 5 | Jun 29, 2018 |
| Lesinurad response | 6 | Mar 19, 2019 |
| Piroxicam response | 6 | Mar 19, 2019 |
| Tamoxifen response | 6 | Mar 6, 2020 |